We use cookies to make it easier for you to use our website and give you a better experience. We aggregate the information we get through cookies from users like you, and analyze that data to better understand user behavior and help us improve the website. We do not give or sell the data you provide through cookies to any third party for any purpose (such as advertising or marketing). By using this website, you consent to Organogenesis using cookies for these purposes. You may change your settings anytime by clicking on the “Security” tab on your browser. Note that Organogenesis is located in the United States, and the U.S. has not yet been determined to have “adequate” data privacy safeguards by the EU; despite any inherent risks in the transfer of data from the EU, Organogenesis takes the security of your information seriously. To read our privacy policy, click here.

Commitment to Ethics and Compliance

Organogenesis, Inc. is committed to the highest standards of ethical conduct and regulatory compliance. We have established a Comprehensive Compliance Program that is reasonably designed to prevent and detect violations of our Standards of Conduct and applicable healthcare laws and regulations. Our Comprehensive Compliance Program is tailored to the size, organizational structure, operational activities and resources of Organogenesis to meet compliance goals consistent with our corporate ethics and with the statutory requirements of California Health and Safety Code §§119400-119402.

The Comprehensive Compliance Program recognizes that compliance with healthcare laws is dynamic. Accordingly, we may revise it to reflect changes in company operations, the Compliance Program Guidance for Pharmaceutical Manufacturers published by the Office of Inspector General for the U.S. Department of Health and Human Services, the PhRMA & AdvaMed Codes on Interactions with Health Professionals, and applicable laws.

The current version of the Comprehensive Compliance Program may be viewed by clicking on the link below:

Comprehensive Compliance Program (PDF, 61 Kb)

To the best of our knowledge, we are in material compliance with the Comprehensive Compliance Program and accordingly, have established the elements outlined and have set up procedures to implement the program's requirements. This declaration is made as of February 1, 2006.

Please feel free to contact us at 1-888-432-5232 to obtain a written copy of this declaration or our Comprehensive Compliance Program.
You need to have Adobe® Acrobat® installed to view PDF files. If you do not have Acrobat® Reader®, you can download it for free from Adobe® website. Download Adobe Acrobat Reader

Adobe® Reader® is a registered trademark of Adobe Systems, Inc.

© 2007 Organogenesis. All rights reserved. | California Compliance Law Declaration


3. Falanga V, Sabolinski ML. A bilayered living skin construct (Apligraf®) accelerates complete closure of hard-to-heal venous ulcers. Wound Repair Regen. 1999;7:201-207.

4. Veves A, Falanga V, et al. Graftskin, a human skin equivalent, is effective in management of non-infected neuropathic diabetic foot ulcers. Diabetes Care. 2001;24:290-295